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356Monosomal Karyotype Provides Better Prognostic
Prediction after Allogeneic Stem Cell Transplantation
in Patients with Acute Myelogenous Leukemia
Betul Oran,1 Michelle Dolan,2 Qing Cao,1 Claudio Brunstein,1
Erica Warlick,1 Daniel Weisdorf1We studied cytogenetic risk grouping schemes to stratify patients with acute myelogenous leukemia (AML)
(n 5 212) into prognostically distinct subgroups for relapse incidence (RI), progression-free survival (PFS),
and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT). Patients were di-
vided according to cytogenetic abnormalities based on the Medical Research Council, Southwest Oncology
Group, Cancer and Leukemia Group B (CALGB), Dana-Farber, and recently described monosomal karyo-
type (MK) classification schemes and analyzed separately for first complete remission (CR1; n 5 134) and
beyond (CR21; n 5 78). Multivariate analysis was performed after adjusting for age, conditioning intensity,
donor type, and cytomegalovirus serology status. Although none of the covariates was associated with OS in
CR1, the presence of MK (MK1) was associated with worse RI and PFS (hazard ratio [HR], 3.3, P5 .01 and
HR, 2.0, P5 .05, respectively). No other classification scheme was predictive of outcomes in CR1. In CR21,
for RI, only MK1was predictive of poor outcome (HR, 3.7; P5.03). For PFS, all 5 classification schemes were
predictive, and for OS, both the MK1 and CALGB adverse karyotypes were predictive. In addition to cyto-
genetics, nonmyeloablative conditioning was associated with decreased PFS and OS in patients in CR21 in all
models. Our results indicate that among all classification schemes, MK classification can identify a subgroup
with very poor prognosis in patients with AML after allogeneic HSCT.
Biol Blood Marrow Transplant 17: 356-364 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: Acute myeloid leukemia, Cytogenetics, Monosomal karyotype, Hematopoietic stem cell
transplantationINTRODUCTION
Cytogenetic findings at the time of diagnosis
represent the single most important prognostic factor
in acute myelogenous leukemia (AML). This is based
on the ability of cytogenetic abnormalities to predict
response to induction therapy, risk of relapse, and over-
all survival (OS) [1-3]. It also has been shown that
cytogenetic abnormalities at diagnosis are associated
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The 3 largest studies to date analyzing risk stratifi-
cation by cytogenetics are cooperative group efforts
from the Medical Research Council (MRC), South-
west Oncology Group/Eastern Cooperative Oncology
Group (SWOG/ECOG), and Cancer and Leukemia
Group B (CALGB) [7-9]. Although risk group
assignments vary among these clinical study groups,
the coexistence of multiple clonal cytogenetic
abnormalities termed a complex karyotype (defined
as presence of a clone with either 3 or 5 unrelated
cytogenetic abnormalities) is universally considered
unfavorable. Because most patients involved in these
cooperative group studies did not receive allogeneic
HSCT for postremission or salvage therapy, another
classification scheme for AML patients treated with
allogeneic HSCT was proposed recently [10]. In that
study, distinct from the previous cooperative group re-
ports, cytogenetic abnormalities either at diagnosis or
at the time of allogeneic HSCT transplantation were
analyzed in relation to disease status before transplan-
tation. In the Dana-Farber (DF) classification scheme,
Biol Blood Marrow Transplant 17:356-364, 2011 357MK Predicts Very Poor Prognosis in AML after HSCTabnormalities of chromosome 5 and 7 were included in
the standard-risk group, and multiple clonal cytoge-
netic abnormalities were still considered a risk factor.
Although there is a consensus forusing complexkar-
yotype in clinical decision algorithms for risk-adapted
treatment, the aforementioned classification schemes
did not resolve the prognostic value of different cytoge-
netic abnormalities, although they did recognize spe-
cific numerical and structural abnormalities. Recently,
the Dutch-Belgian Haemato-Oncology Cooperative
Group/SwissGroupanalyzed thecontributionofdiffer-
ent components of complex cytogenetic abnormalities,
and defined monosomal karyotype (MK) as a predictor
of very poor prognosis [11]. MK is defined as the pres-
ence of 2 or more autosomal monosomies or a single
autosomal monosomy in the presence of additional
structural abnormalities [11]. Compared with complex
karytope for determining risk status, patients with MK
(MK1) but without complex karyotype had a similar
(very poor) prognosis as all MK1 patients, whereas
patients with complex karyotype but without MK had
better disease outcomes. Thus, that group suggested
thatMK status provides a definitively adverse stratifica-
tionwithmore prognostic validity than the traditionally
defined complex karyotype.
In the present study, we investigated which cytoge-
netic risk grouping scheme provided the best prognos-
tic information for disease outcome in AML patients
receiving allogeneic HSCT in remission.PATIENTS AND METHODS
Patients with AMLwho received allogeneicHSCT
using bone marrow, peripheral blood progenitor, and
umbilical cord blood (UCB) cells at the University of
Minnesota between January 1995 and December
2007 were included in this study. Patients with a previ-
ous diagnosis of myelodysplastic syndrome (MDS) or
a myeloproliferative disorder (MPD) were included if
they progressed to AML. Allogeneic donors were
HLA-compatible related donors (low-resolution
matched for HLA-A and -B and high-resolution
matched for HLA-DRB1), or UCB grafts matched
for at least 4 of 6 HLA-A, -B, and -DRB1 and, for
double-UCB grafts, also matched for at least 4 of 6
loci to each other using previously published UCB se-
lection criteria [12,13]. Patients with a previous
allogeneic HSCT were excluded. Cytogenetic
analysis at the time of diagnosis was required for this
analysis; 4 patients without such cytogenetic data
were excluded. A total of 212 patients with AML
were eligible for this study. All patients were treated
with protocols approved by the Institutional Review
Board (IRB). All patients provided written informed
consent. The IRB granted permission for this analysis.Conditioning Regimens and GVHD Prophylaxis
A total of 118 patients received a myeloablative
(MA)conditioning regimenconsistingof cyclophospha-
mide 60mg/kg i.v. daily for 2 days and 1320 cGy of total
body irradiation (TBI) given in 8 fractions. Eighty-
five of these 118 patients also received fludarabine
25 mg/m2 for 3 days. Ninety-four patients received
a reduced-intensity conditioning (RIC) regimen con-
sisting of fludarabine 40 mg/m2 i.v. daily for 5 days
and 200 cGy TBI with either cyclophosphamide 50
mg/kg i.v. for 1 day (n5 90) or busulfan 2 mg/kg orally
every 12hours for 4doses (n5 4).Graft-versus-host dis-
ease (GVHD) prophylaxis used cyclosporine (from day
23 to at least day1100) given with either mycopheno-
latemofetil (fromday -3 to at least day130) (n5 128) or
methotrexate (n5 76), or alone (n5 8).Cytogenetics and Statistical Analysis
Leukemia cytogenetic data at diagnosis were ex-
tracted from the patients’ medical records. A patholo-
gist at our institution’s cytogenetics laboratory
reviewed the cytogenetic data, in accordance with the
International System for Human Cytogenetic No-
menclature. An abnormality was considered clonal
and thus mentioned in the karyotype when at least 2
metaphases had the same aberration in cases of a struc-
tural abnormality or an extra chromosome. If there was
a monosomy, it had to be present in at least 3 meta-
phases. Karyotype abnormalities were grouped ac-
cording to published criteria of the CALGB,
SWOG/ECOG, MRC, DF, and recently defined
MK classification schemes [7-11].
The primary study endpoint was cumulative
relapse incidence (RI). Other study endpoints included
probability of progression-free survival (PFS) and
overall survival (OS). PFS was defined as survival
without disease progression or relapse; patients alive
without disease progression or relapse were censored
at the time of last follow-up. OS was defined as the
time from stem cell infusion to death from any cause.
Patients who were alive were censored at the time of
last contact. Relapse was defined as disease recurrence
at any site. PFS and OS were calculated using the
Kaplan-Meier method. Univariate comparisons of all
endpoints were done using the log-rank test. A cumu-
lative RI rate (with 95% confidence interval [CI]) was
constructed reflecting time to relapse and time to
nonrelapse death as competing risks.
A Cox proportional hazards model or the Gray-
Fine method for competing hazards was used for
multivariate regression. Only 1 cytogenetic risk classi-
fication scheme was included in each multivariate
model, and thus 5 different regression models were
analyzed for each outcome. Variables were included
in the multivariate model if they were conceptually
important, or if they approached (P\ .10) or attained
358 Biol Blood Marrow Transplant 17:356-364, 2011B. Oran et al.statistical significance in the univariate regression. The
variables cytogenetic risk classification, recipient age at
transplantation, donor cytomegalovirus (CMV) sero-
logic status, conditioning regimen, and donor type
were included in everymodel. AllP valueswere 2-sided.
Statistical analyses were performed using SAS 8.2
and 9.1 (SAS Institute, Cary, NC). The analyses
were based on follow-up through September 2008.RESULTS
Patient Characteristics
Patient, disease, and transplant characteristics are
summarized in Table 1. The median age at transplanta-Table 1. Patient Demographic Data
CR1 (n 5 134) CR2+ (n 5 78)
Median age, years 46.2 44.8
Age $ 60 years, n (%)
No 120 (89.6) 70 (89.8)
Yes 14 (10.4) 8 (10.2)
Antecedent hematologic
disorder, n (%)
Yes 22 (16.4) 5 (6.4)
No 112 (83.6) 73 (93.6)
Therapy-related AML, n (%)
Yes 6 (4.5) 1 (1.3)
No 128 (95.5) 77 (98.7)
Conditioning regimen, n (%)
MA 78 (58.2) 40 (51.3)
RIC 56 (41.8) 38 (48.7)
Donor source, n (%)
MSD 76 (56.7) 29 (37.2)
UCB 58 (43.3) 49 (62.8)
Cytogenetic classification
schemes, n (%)
CBF 5 (3.7) 7 (9.0)
CN 48 (35.8) 41 (52.6)
MK- 62 (46.3) 16 (20.5)
MK+ 17 (12.7) 6 (7.7)
Excluded 2 (1.5) 8 (10.3)
DF, n (%)
Favorable 6 (4.5) 14 (17.9)
Standard 91 (67.9) 54 (69.2)
Adverse 37 (27.6) 10 (12.8)
SWOG/ECOG, n (%)
Favorable 6 (4.5) 14 (17.9)
Intermediate 56 (41.8) 43 (55.1)
Unfavorable 66 (49.3) 15 (19.2)
Unknown significance 6 (4.5) 6 (7.7)
MRC, n (%)
Favorable 7 (5.2) 15 (19.2)
Intermediate 93 (69.4) 53 (67.9)
Unfavorable 34 (25.4) 10 (12.8)
CALGB, n (%)
Favorable 6 (4.5) 8 (10.3)
Intermediate 66 (49.3) 43 (55.1)
Adverse 53 (39.6) 14 (17.9)
Unknown significance 7 (5.2) 5 (6.4)
Excluded 2 (1.5) 8 (10.3)
CR1 indicates first complete remission; CR2+, second or third com-
plete remission; MA, myeloablative; RIC, reduced intensity conditioning;
MSD, matched sibling donor; UCB, umbilical cord blood; MK, monoso-
mal karyotype; CBF, core binding factor; CN, normal cytogenetics; DF,
Dana-Farber; MRC, Medical Research Council; SWOG/ECOG, South-
west Oncology Group/Eastern Cooperative Oncology Group; CALGB,
Cancer and Leukemia Group B.tion for the entire cohort was 45 years (range, 18-69
years). Twenty-two (10%) of the patients were older
than 60 years. Nearly half of the patients in the cohort
had a matched sibling donor (MSD) (n 5 105), and
the other half received UCB (n 5 107; 21 single-unit
grafts and 86 double-unit grafts). A total of 134 patients
(63%)underwent transplantationwhile infirst complete
remission (CR1), 68 (32%) did so while in second CR
(CR2), and the remainder (n5 10) did so while in third
CR (CR3). The patients inCR1 had a greater frequency
of antecedent hematologic disorders, including MDS
and MPD, compared with those in CR2 or CR3 (here-
inafter denoted by CR21) (16.4% vs 6.4%). They also
hadmore frequent diagnostic cytogenetic abnormalities
with adverse/unfavorable prognosis according to the
SWOG/ECOG,MRC, CALGB, and DF classification
schemes (adverse cytogenetics in the 4 schemes: 25.4%-
49.3% in CR1 patients vs 12.8%-19.2% in CR21
patients). Similarly, more CR1 patients were classified
as MK1 or MK negative (MK-) compared with the
CR21 patients, (MK1, 12.7% vs 7.7%; MK-, 46.3%
vs 20.5%). UCB grafts were used in 58 CR1 patients
(43.3%) and in 49 CR21 patients (62.8%) (P # .01).
Basedon thesedifferingdisease andgraft characteristics,
CR1 and CR21 patients were analyzed separately. We
found no interaction between cytogenetics and other
variables in these separate analyses.Cytogenetic Classification
The distributions of favorable-risk, intermediate/
standard-risk, and unfavorable/adverse-risk groups were
similar in the SWOG/ECOG, MRC, CALGB, and DF
classification schemes (Table 2); however, cytogenetic
classification was concordant in only 131 patients
(62%). Ten patients (5%) were in the favorable-risk
group, 89 (42%) were in the intermediate/standard-risk
group, and 32 (15%) were in the unfavorable/adverse-
risk group in all 4 of these classification schemes. Among
the remaining 79 patients, 55 (26%)were classified as un-
favorable/adverse in one scheme and as intermediate/
standard in another scheme. Sixteen patients (7%) were
classified as unknown significance, and 10 (5%) were
excluded in at least one scheme.Whenpatientswere clas-
sified according to the MK scheme, 12 (5.7%) had core
binding factor (CBF) abnormalities, 89 (42%)were cyto-
genetically normal (CN), 78 (36.8%) had non-CBF
abnormalities but were MK-, and 23 (10.8%) had non-
CBF abnormalities but were MK1. Ten patients with
t(15;17) were not included in the MK scheme. The 23
MK1 patients with very poor prognosis were grouped
as unfavorable/adverse in all other classification schemes
except MRC, in which 2 of these 23 patients were classi-
fied as intermediate risk.
Twenty-six patients (12.3%) had at least a single
autosomal monosomy, and 10 of these 26 (38.5%)
had 2 or more autosomal monosomies. The single
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Biol Blood Marrow Transplant 17:356-364, 2011 359MK Predicts Very Poor Prognosis in AML after HSCTmost common autosomal monosomy was monosomy
7, detected in 14 patients (6.6%). Twenty-two of the
26 patients with at least a single autosomal monosomy
(84.6%) were classified as MK1. Four patients had
a single autosomal monosomy without structural
abnormalities and thus were classified as MK-.
Relapse Events by Cytogenetic Abnormalities
Of the 212 patients evaluated, 70 (33%) demon-
strated post-HSCT relapse of AML on follow-up.
These patients included 40 in CR1 (30%) and 30 in
CR21 (38.5%). Relapse occurred at a median of 5.1
months (range, 0.7-75.8 months) in the CR1 patients
and 5.7 months (range, 0.9-53.4 months) in the
CR21 patients. Only the MK scheme could signifi-
cantly predict the risk of relapse in the CR1 patients.
Risk groupings by the SWOG/ECOG, MRC,
CALGB, and DF schemes were not significantly asso-
ciated with RI, although CALGB showed a trend
toward a higher cumulative RI in the unfavorable/
adverse-risk group patients (Table 3). MK1 patients
had a significantly increased risk of relapse (hazard ratio
(HR)53.3, p50.01, 95% CI51.2-8.8) compared with
CN patients, with a cumulative RI of 62% (95% CI,
36%-89%) (Figure 1A and Table 3). Eleven of 17
MK1 patients relapsed, with a median time to relapse
of 6.1 months. The cumulative RI was 23% (95% CI,
11%-35%) in CN patients and 22% (11%-33%) in
MK- patients, with a respective median time to relapse
of not reached and 78 months. Patients who received
RIC demonstrated a trend toward higher RI in models
using the SWOG/ECOG, MRC, CALGB, and DF
risk classification schemes, but this trend did not reach
statistical significance. A similar association was not
observed when MK was included as the cytogenetic
classification scheme in the multivariate regression
model.
Similarly, in CR21 patients, only the MK scheme
was able to identify a risk group with a significantly
higher RI (Table 3). MK1 was associated with in-
creased RI (HR, 3.8, 95% CI, 1.1-12.15; P 5 .03)
with a cumulative RI of 67% (95% CI, 14%-100%)
and a median time to relapse of 2.5 months
(Figure 1B). In contrast, CN patients had a cumulative
RI of 32% (95%CI, 17%-47%), with a median time to
relapse not reached, andMK- patients had a cumulative
RI of 50% (95% CI, 24%-76%) and a median time to
relapse of 16.7 months. All but 1 of the relapses oc-
curred within the first 2 years after allogeneic
HSCT. The CALGB scheme, but not the SWOG/
ECOG, MRC, and DF schemes, showed a trend
toward higher RI in unfavorable/adverse-risk group
patients that did not reach statistical significance.
The cumulative RI was not associated with donor
type in CR1 and CR21 patients in any of the models,
and the RI was comparable in patients receiving MSD
and those receiving UCB.
Table 3. Multivariate Models For Disease Outcomes with the Different Cytogenetic Classification Schemes
Cumulative RI PFS OS
CR1 CR2+ CR1 CR2+ CR1 CR2+
HR P HR P HR P HR P HR P HR P
SWOG/ECOG
Intermediate 1.00 1.00 1.00 1.00 1.00 1.00
Favorable 2.19 .35 0.83 .74 2.39 .08 0.95 .90 2.02 .16 0.67 .39
Unfavorable 1.47 .28 2.00 .13 1.34 .23 2.43 .02 1.27 .34 1.83 .12
Unknown significance 0.68 .70 1.43 .50 1.16 .78 1.70 .31 0.89 .85 1.94 .21
MRC
Intermediate 1.00 1.00 1.00 1.00 1.00 1.00
Favorable 1.77 .49 0.66 .43 1.73 .27 0.74 .47 1.64 .31 0.54 .19
Unfavorable 1.70 .17 1.67 .33 1.47 .15 2.49 .02 1.58 .10 1.60 .27
CALGB
Intermediate 1.0 1.00 1.00 1.00 1.00 1.00
Favorable 4.89 .03 0.34 .28 3.11 .03 1.45 .47 1.67 .34 1.63 .35
Adverse 1.89 .07 2.34 .06 1.43 .15 3.74 <.001 1.25 .37 2.95 .01
Unknown significance 0.67 .69 .73 .25 1.88 .17 1.75 .32 1.57 .37 2.08 .20
DF
Standard 1.00 1.00 1.00 1.00 1.00 1.00
Favorable 1.70 .13 0.78 .63 2.26 .10 0.89 .78 1.92 .18 0.63 .32
Adverse 2.12 .65 2.31 .08 1.43 .16 2.72 .01 1.30 .33 1.90 .12
MK
CN 1.00 1.00 1.00 1.00 1.00 1.00
CBF 2.87 .19 0 <.01 2.66 .08 1.14 .82 2.23 .15 1.34 .6
MK2 0.91 .82 1.73 .20 1.42 .17 2.03 .06 1.36 .24 2.05 .06
MK+ 3.32 .01 3.75 .03 2.01 .05 5.89 <.01 1.71 .15 2.93 .04
PFS indicates progression free survival; OS, overall survival; CR1, first complete remission; CR2+, second or third complete remission; HR, hazard ratio;
p, p value; MRC, Medical Research Council; SWOG/ECOG, Southwest Oncology Group/Eastern Cooperative Oncology Group; CALGB, Cancer and
Leukemia Group B; DF, Dana-Farber; MK, monosomal karyotype; CN, normal cytogenetics; CBF, core binding factor.
Bold HR and p values indicate statistically significant findings.
All regression analyses were adjusted for pertinent clinical variables, including age, donor type, CMV serologic status, conditioning intensity, and a single
cytogenetic classification scheme. In all 5 models, in CR2+ patients, RIC was associated with worse outcome (CALGB: PFS: HR, 3.0, P5.01; OS: HR, 3.0,
P < .01; MRC: PFS: HR, 3.0, P5.01; OS: HR, 3.8, P < .01; SWOG/ECOG: PFS: HR, 3.6, P5.01; OS: HR, 3.2, P5.01; DF: PFS: HR, 3.0, P5.01; OS: HR, 2.8,
P 5 .02; MK: PFS: HR, 3.8, P < .01; OS: HR, 3.3, P 5 .01). Having an MSD was associated with worse OS in the SWOG/ECOG model in CR2+ patients
(HR, 2.0; P 5 .05).
360 Biol Blood Marrow Transplant 17:356-364, 2011B. Oran et al.PFS by Cytogenetic Abnormalities
The 3-year PFS was 39% for CR1 patients and
34% for CR21 patients, and median time to progres-
sion was 10.5 and 9.1 months, respectively. In CR1 pa-
tients, only MK1 was found to be associated with
worse PFS (HR, 2.0; P 5 .05). The 3-year PFS was
19%, with a median time to progression of 5.7 months
(Figure 1C and Table 4). The 3-year PFS was 37% for
MK- patients and 49% for CN patients, with median
time to progression of 8.2 and 21.4 months, respec-
tively. None of the other 4 models could predict PFS
based on different classification schemes, and in all of
these 4 models, no other variable significantly
predicted PFS.
All 5 cytogenetic classifications schemes were sig-
nificantly associated with PFS in CR21 patients
(Table 4), but only the MK scheme could identify
a very poor prognostic group, MK1 (HR, 5.9;
P \.01) versus a poor prognostic group, MK- (HR,
2.0; P5 .06). Median PFS was 2 months for MK1 pa-
tients, 7.9 months for MK- patients, and 16 months for
CN patients (Figure 1D and Table 4). In all 5 models,
patients who received an RIC regimen had a worse
PFS compared with patients who received MA condi-tioning (HR, 3-3.8) (Table 3). None of the other
variables was associated with PFS in all 5 models.
Donor type was not associated with PFS in any of
the models. MSD andUCB recipients had comparable
PFS in CR1 and CR21 (34% vs 46%, P 5 .60 and
35% vs 38%, P 5 .90, respectively)
OS by Cytogenetic Abnormalities
The median follow-up for 86 surviving patients
was 46 months (range, 8.5-163.6 months) and was
comparable for CR1 and CR21 patients (48.6 and
44.3 months, respectively). In CR1, 80 patients
(60%) died at a median of 19 months and in CR21,
46 patients (59%) died at a median of 20.2 months.
In CR1, none of the variables, including cytogenetic
classification scheme, was associated with OS. Even
MK1 patients had a comparable OS with CN and
MK2 patients (Figure 1E and Table 4). In CR2, only
the regression models with the MK and CALGB
classification schemes were able to predict poor risk
for OS. Adverse-risk group patients by the CALGB
scheme had worse OS compared with intermediate-
risk patients (HR, 2.9; P 5 .01). Similarly, MK1 and
MK- patients had worse OS compared with CN
Figure 1. Cumulative incidence of relapse, progression free and overall survival in CR1 (A, C and E respectively) and CR2+ (B, D and F respectively)
AML patients after allogeneic hematopoietic stem cell transplantation based on their diagnostic cytogenetics grouped per monosomal karyotype. Core
binding factor (CBF) abnormalities; normal karyotype (CN); non-CBF abnormalities but monosomal karyotype (MK) negative (MK2); and non-CBF
abnormalities but MK positive (MK+). MK refers to two or more autosomal monosomies or one autosomal monosomy with at least one structural
abnormality [11].
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spectively). Median OS was 2.4 months for MK1 pa-
tients, 9.2 months for MK- patients, 34.4 months for
CN patients, and 2.6 months for CBF AML patients
(Figure 1F). Median OS was 3.7, 34.4, and 2.6 months
for unfavorable-risk, intermediate-risk, and favorable-
risk groups in the CALGB scheme. In bothmodels, re-
ceipt of an RIC regimen was associated with poorer
OS (HR, 0.3, P 5 .01 in the CALGB model; HR,
0.3, P 5 .01 in the MK model).
Donor type was not associated with OS in any of
the models. MSD andUCB recipients had comparable
OS in CR1 and CR21 (27% vs 30%, P5 .60 and 38%
vs 26%, P 5 .90, respectively).Table 4. Three-Year Cumulative RI and Kaplan-Meier Estimates (w
MK Classification
CR1
MK n 3-Year RI 3-Year PFS 3-Year OS
CBF 5 40% (2%-78%) 20% (<1%-58%) 40% (5%-75%)
CN 48 23% (11%-35%) 49% (35%-63%) 51% (36%-64%)
MK2 62 22% (11%-33%) 37% (24%-48%) 38% (26%-50%)
MK+ 17 62% (36%-89%) 19% (4%-42%) 40% (18%-62%)
PFS indicates progression free survival; OS, overall survival; CR1, first complete
karyotype; CN, normal cytogenetics; CBF, core binding factor.DISCUSSION
The prognostic impact of cytogenetic findings in
patients with AML after allogeneic HSCT differed
depending on the cytogenetic prognostic classification
scheme used. The 3 cooperative group cytogenetic
classification schemes studied were predictive for
some, but not all, outcomes after HSCT. These 3
cooperative group studies were designed to predict
disease outcome after induction therapy in AML,
and only 9%-14% of patients received allogeneic
HSCT as part of their treatment. One interesting
finding was that the DF classification scheme, based
on retrospective analyses of patients treated withith 95% CIs) of PFS andOS in CR1 and CR2+ Patients Based on
CR2
n 3-Year RI 3-Year PFS 3-Year OS
7 0% 29% (4%-61%) 43% (10%-73%)
41 32% (17%-47%) 44% (29%-58%) 48% (32%-62%)
16 50% (24%-76%) 19% (4%-40%) 27% (8%-51%)
6 67% (14%-100%) 0% 17% (<1%-52%)
remission; CR2+, second or third complete remission; MK, monosomal
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come. In that study, cytogenetics at either diagnosis
or relapse were used based on disease status at
HSCT. The prognostic significance of cytogenetics
at relapse has not been clearly established. Impor-
tantly, the acquisition of further aberrations beyond
those present at diagnosis has been reported to occur
more frequently in patients with unfavorable karyo-
types compared with all others [14,15]. In the
current study, we analyzed only cytogenetics at the
time of diagnosis, which might explain at least some
of the differences in our observations. All of the
patients in our study were in complete remission at
HSCT, in contrast to approximately 70% of the
patients in that study. Considering the association
between poor prognostic cytogenetics at diagnosis
and lower CR rates with resistant disease [16], these
data suggest that the beneficial effects of allogeneic
HSCT in poor-risk cytogenetic patients in remission
might be obscured in an analysis including patients
with active leukemia.
Allogeneic HSCT with an MSD was found to im-
prove outcomes for unfavorable/adverse-risk AML in
CR1 in some studies [6,7], whereas other studies
reported poor outcomes, even after allogeneic
HSCT [4,6,17,18]. A recent meta-analysis including
more than 6000 patients in clinical trials comparing al-
logeneic HSCT and nonallogeneic HSCT revealed
that HSCT for AML in CR1 increased the projected
5-year OS rates to 52% for intermediate-risk patients
and 31% for poor-risk patients, similar to our findings
for both groups [19]. Similarly, registry data showed
that with patients with an MUD achieved a 5-year
OS of approximately 30%, with cytogenetics (by the
SWOG/ECOG classification scheme) having no in-
fluence on disease outcome [20]. These results suggest
that clinical outcomes improve with allogeneic HSCT
even in unfavorable/adverse-risk patients as well as
intermediate/standard-risk patients.
Allogeneic HSCT yields disease-free survival
(DFS) rates of 30%-50% in patients in CR2 with
MSD [21]. In patients lacking an MSD, DFS and OS
of35%-40%was reported withMUD, with no influ-
ence of unfavorable cytogenetics on DFS and OS, al-
beit with higher relapse rates [20]. Similarly, in our
study, CR21 patients had OS independent of cytoge-
netics by the SWOG/ECOG and MRC classification
schemes after allogeneic HSCT. The 3-year OS was
approximately 30% in unfavorable/adverse-risk pa-
tients by both classification schemes, likely better
than the 8%-30% (dependent on cytogenetics and du-
ration of CR1) seen with conventional chemotherapy
[22-24].
The CALGB scheme could better predict out-
comes compared with the SWOG/ECOG, MRC,
and DF schemes. Although all 3 of the latter schemes
were able to identify a poor prognostic group forPFS in CR21 patients, only the CALGB classification
scheme could predict OS in these same patients.
Unfavorable-risk group by the CALGB scheme also
demonstrated a trend toward increased RI in CR1
and CR21 patients, but this trend did not reach statis-
tical significance.When the analyses were repeated for
other cytogenetic classification schemes after the ex-
clusion of patients excluded by the CALGB classifica-
tion scheme, this important association of the CALGB
scheme with outcome did not change. This is in con-
trast to previous findings showing that the variability
among cytogenetic risk classification schemes was
not accompanied by major variability in their associa-
tion with outcomes after allogeneic HSCT [7,20,25].
The CALGB classification scheme describes a lower
reported 5-year OS in the unfavorable-risk group
(5%) compared with the 11% and 14% reported by
SWOG/ECOG and MRC schemes, respectively. Al-
though this difference might be explained by differ-
ences in patient disease characteristics and treatments
received, our findings also suggest the utility of the
CALGB scheme for identifying a worse prognostic
group.
The most striking finding in the present study was
reliable and reproducible identification of a very poor
prognosis group by the MK classification scheme with
worse relapse, PFS, and OS after allogeneic HSCT. In
contrast to the other classification schemes, the MK
scheme was predictive for nearly all outcomes in
CR1 and CR21 patients, and suggests that not only
loss of chromosomes25 or –7, but also any type of au-
tosomal monosomy in AML, is associated with a poor
outcome [11]. In the MK classification scheme, the
presence of trisomies or tetrasomies, marker or ring
chromosomes, did not provide additional prognostic
value compared with monosomal abnormalities.
Only structural cytogenetic abnormalities conveyed
additional risk, with a reported 4-year OS of \4%.
Our HSCT results of 40% OS in MK1, CR1 patients,
which is comparable to the findings in MK- and CN
patients in CR1, suggest that allogeneic HSCT in
CR1 has the potential to improve outcomes even in
this very poor prognostic group. However, the cumu-
lative RI of 62% and median time to relapse of 6.3
months indicate the urgent need for alternative strate-
gies to improve results. Similar dismal results, with
17% OS, a cumulative RI of 67%, and a median time
to relapse of 2.7 months, were observed in MK1,
CR21 patients.
In our study population, 13% of the AML patients
had an antecedent hematologic disorder, including
MDS andMPD. There is no consensus among cytoge-
netic classification schemes for patients with those an-
tecedent disorders. We included those patients in our
analyses, because subset analyses excluding patients
with antecedent MDS and MPD showed similar
recognition of the largest proportion of unfavorable/
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sification schemes. Multivariate modeling excluding
these cases also showed similar findings, as well as an
association with poorest outcomes for the high-risk
cases identified by the MK and CALGB classification
schemes (data not shown).
The present study has some limitations. In this
retrospective cohort study with a modest number of
patients, we had very few favorable-risk patients in
CR1 and observed disappointing outcomes though
these patients received MA conditioning and MSD
grafts. They had frequent early nonrelapse mortality
plus a high RI, worse than some published data [19].
We could not analyze confounding factors that might
account for this, such asWBC count at diagnosis, num-
ber of induction cycles to achieve CR, and time to CR
from diagnosis, because the data were missing for pa-
tients who were initially treated elsewhere. In addition,
we could not analyze molecularly defined prognostic
factors that might refine the prognostic classification
of CNpatients [26]. Despite these limitations, however,
our study demonstrates that allogeneic HSCT might
have the potential to overcome the poor prognosis asso-
ciated with unfavorable/adverse cytogenetics; further
investigation is needed. Our study is also unique in
that more than half of the patients received UCB.
Importantly, our study confirms the findings of
Breems et al. [11] and shows that the MK classification
scheme is able to identify a group with a very poor
prognosis for nearly all study endpoints, even after al-
logeneic HSCT. The unacceptably high RI in MK1,
CR1 patients clearly indicates the urgent need for
novel therapies in this very poor prognostic group.ACKNOWLEDGMENTS
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